Skip to main content

Unsolicited Bid Causes Applied Imaging to Raise Price Genetix Must Pay for It

NEW YORK (GenomeWeb News) — Applied Imaging today said that an unsolicited bid from a third party to acquire all of its outstanding shares has caused it to the raise by around 24 percent the original price that suitor Genetix will pay to acquire it.
 
Genetix will now pay around $22.7 million for Applied Imaging after the companies amended the terms of the acquisition on Nov. 2 following the unsolicited bid.
 
As GenomeWeb News reported in September, Genetix said it would acquire Applied Imaging for $18.3 million in cash, or $3.06 per share. At the time the companies said the deal would close in the fourth quarter
 
Yesterday’s amendment increased from $3.70 per share to $3.80 the amount Genetix will pay for Applied Imaging's stockholders per share.
 
The firms said they expect to meet on Nov. 21 to approve the proposed acquisition.

The Scan

UK Funds to Stay Ahead of Variants

The UK has announced a further £29.3 million to stay on top of SARS-CoV-2 variants, the Guardian reports.

Push for Access

In a letter, researchers in India seek easier access to COVID-19 data, Science reports.

Not as Cold

Late-stage trial results are expected soon for an RNA-based vaccine that could help meet global demand as it does not require very cold storage, the New York Times writes.

Genome Research Papers on Microbes' Effects on Host Transfer RNA, Honeybee Evolution, Single-Cell Histones

In Genome Research this week: influence of microbes on transfer RNA patterns, evolutionary relationships of honeybees, and more.